Ting Song1, Peiran Wang1, Xiaoyan Yu2, Anhui Wang3, Gaobo Chai2, Yudan Fan2, Zhichao Zhang1. 1. State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, China. 2. School of Life Science and Technology, Dalian University of Technology, Dalian, China. 3. School of Innovation Experiment, Dalian University of Technology, Dalian, China.
Abstract
BACKGROUND AND PURPOSE: The biological significance of the multi-site phosphorylation of Bcl-2 at its loop region (T69, S70 and S87) has remained controversial for decades. This is a major obstacle for understanding apoptosis and anti-tumour drug development. EXPERIMENTAL APPROACH: We established a mathematical model into which a phosphorylation and de-phosphorylation process of Bcl-2 was integrated. Paclitaxel-treated breast cancer cells were used as experimental models. Changes in the kinetics of binding with its critical partners, induced by phosphorylation of Bcl-2 were experimentally obtained by surface plasmon resonance, using a phosphorylation-mimicking mutant EEE-Bcl-2 (T69E, S70E and S87E). KEY RESULTS: Mathematical simulations combined with experimental validation showed that phosphorylation regulates Bcl-2 with different dynamics depending on the extent of Bcl-2 phosphorylation and the phosphorylated Bcl-2-induced changes in binding kinetics. In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 μM paclitaxel treatment. In contrast, Bcl-2 phosphorylation enhanced the anti-apoptotic ability of Bcl-2 towards other BH3-only proteins Bim, Bad and Puma, throughout the entire phosphorylation procedure. CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide.
BACKGROUND AND PURPOSE: The biological significance of the multi-site phosphorylation of Bcl-2 at its loop region (T69, S70 and S87) has remained controversial for decades. This is a major obstacle for understanding apoptosis and anti-tumour drug development. EXPERIMENTAL APPROACH: We established a mathematical model into which a phosphorylation and de-phosphorylation process of Bcl-2 was integrated. Paclitaxel-treated breast cancer cells were used as experimental models. Changes in the kinetics of binding with its critical partners, induced by phosphorylation of Bcl-2 were experimentally obtained by surface plasmon resonance, using a phosphorylation-mimicking mutant EEE-Bcl-2 (T69E, S70E and S87E). KEY RESULTS: Mathematical simulations combined with experimental validation showed that phosphorylation regulates Bcl-2 with different dynamics depending on the extent of Bcl-2 phosphorylation and the phosphorylated Bcl-2-induced changes in binding kinetics. In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 μM paclitaxel treatment. In contrast, Bcl-2 phosphorylation enhanced the anti-apoptotic ability of Bcl-2 towards other BH3-only proteins Bim, Bad and Puma, throughout the entire phosphorylation procedure. CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide.
Authors: Paul G Ekert; Anissa M Jabbour; Anand Manoharan; Jacki E Heraud; Jai Yu; Miha Pakusch; Ewa M Michalak; Priscilla N Kelly; Bernard Callus; Thomas Kiefer; Anne Verhagen; John Silke; Andreas Strasser; Christoph Borner; David L Vaux Journal: Blood Date: 2006-05-16 Impact factor: 22.113
Authors: Claudio Stefanelli; Benedetta Tantini; Monia Fattori; Ivana Stanic'; Carla Pignatti; Carlo Clo; Carlo Guarnieri; Claudio M Caldarera; Caroline A Mackintosh; Anthony E Pegg; Flavio Flamigni Journal: FEBS Lett Date: 2002-09-11 Impact factor: 4.124
Authors: Amy M Mingo-Sion; Peter M Marietta; Erich Koller; Douglas M Wolf; Carla L Van Den Berg Journal: Oncogene Date: 2004-01-15 Impact factor: 9.867